interferon - versus Immunostimulants drugs - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.20 [0.65, 2.23]< 10%2 studies (2/-)27.6 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.52 [0.02, 15.78]< 10%1 study (1/-)64.5 %some concernnot evaluable moderateimportant-
clinical improvement 1.54 [1.12, 2.12]> 10%2 studies (2/-)99.6 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 2.86 [1.24, 6.62]> 10%1 study (1/-)99.3 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 4.26 [1.10, 16.44]> 10%1 study (1/-)98.2 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.83 [0.41, 8.14]> 10%1 study (1/-)78.5 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.54 [1.12, 2.12]> 10%2 studies (2/-)99.6 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.52 [0.02, 15.78]< 10%1 study (1/-)64.5 %some concernnot evaluable moderateimportant-
viral clearance 7.68 [0.91, 65.15]> 10%1 study (1/-)96.8 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 1.74 [1.10, 2.75]> 10%1 study (1/-)99.1 %some concernnot evaluable moderateimportant-
viral clearance by day 14 1.74 [0.71, 4.29]> 10%1 study (1/-)88.7 %some concernnot evaluable moderateimportant-
viral clearance by day 7 2.20 [0.95, 5.10]> 10%1 study (1/-)96.7 %some concernnot evaluable moderateimportant-

safety endpoints 00

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.